Zai Lab Announces $77.5 Million Collaboration for Incyte’s PD-1 mAb

Zai Lab
Published on: July 2, 2019

Zai Lab of Shanghai entered a $77.5 million collaboration and license agreement with Incyte to develop Incyte’s investigational anti-PD-1 mAb in Greater China. Zai will pay Incyte $17.5 million up front, plus up to $60 million in development, regulatory and commercial milestones, as well as tiered royalties. INCMGA0012 is currently being evaluated as a monotherapy in patients with endometrial cancer. Zai intends to test the PD-1 in combination with other of its cancer treatments, including a HER2 candidate and possibly a PARP inhibitor.

Source: China Biotoday

Biotechnology Life Science Medical Device Pharmaceutical